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ABSTRACT   
 
BACKGROUND: Metabolic syndrome is a cluster of risk factors 
that is responsible for the risk of coronary heart disease and stroke. 
Therefore, the aim of this study was to assess the prevalence of 
MetS and its components among T2DM patients. 
METHODS: A cross-sectional study was conducted at the Diabetes 
Clinic of the Hospital, from June to July, 2015. Data were entered 
into EPI INFO software and exported to SPSS 20 for analysis. 
MetS prevalence was estimated using NCEP ATPIII and IDF 
criteria. Anthropometric measurements, investigations of serum 
glucose and lipid profiles were done. Logistic regression analysis 
was used to evaluate associated factors. A P-value ≤ 0.05 was 
considered statistically significant.  
RESULT: A total of 159 participants were included in the study; 
119 (59.7%) were females with mean (±SD) age of (49.8±8.7) year. 
The prevalence of MetS was 66.7% in NCEP-ATP III and 53.5% in 
IDF definitions. The most prevalent component of MetS was 
elevated triglyceride (56.6% in ATPIII and 62.3% in IDF criteria), 
followed by abdominal obesity (61%) IDF and elevated blood 
pressure (55.4%) NCEP-ATPIII criteria. The regression analysis 
showed that increased age, being female, high BMI, having 
diabetes for over 5 years and poor glycemic control were 
significantly associated with metabolic syndrome. 
CONCLUSION: The prevalence of MetS and its components 
among T2DM patients were high, suggesting that diabetic patients 
are at increased risk of CVD and other complications. Efforts 
should be geared towards addressing these abnormalities through 
lifestyle modification, health awareness and medications in order 
to reduce this complication. 
KEYWORDS: NCEP-ATPIII, IDF, Type 2 DM, Metabolic 
syndrome, Ethiopia, University of Gondar Hospital  
 
 
 
 
 
INTRODUCTION  
 
Metabolic syndrome (MetS) is a cluster of 
interconnected dangerous heart attack risk factors 
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that directly increase the risk of cardiovascular 
diseases (CVD), and type 2 diabetes mellitus 
(T2DM). It is a highly prevalent and major public 
health challenge among adults in developed 
countries and an emerging health problem in 
developing countries (1). 
Many international organizations and expert 
groups, such as the World Health Organization 
(WHO), the European Group for the study of Insulin 
Resistance, the National Cholesterol Education 
Program Adult Treatment Panel III (NCEP:ATPIII), 
the American Association of Clinical Endocrinology, 
the International Diabetes Federation (IDF) and the 
American Heart Association/National Heart, Lung 
and Blood Institute have endeavored to integrate all 
the different parameters used to define MetS. 
According to these expert groups, its main 
components are raised fasting plasma glucose, 
dyslipidemia and elevation of arterial blood pressure 
(BP), while abdominal obesity and/or insulin 
resistance (IR) have gained increasing attention as 
the core manifestations of the syndrome (2).  It is 
estimated that around 20-25% of the world’s adult 
population have MetS and they are 3 times as likely 
to have a heart attack compared with people without 
the syndrome (3). The clustering CVD risk factors 
that illustrates MetS is now considered to be the 
driving force for a new CVD epidemic and people 
with T2DM who have MetS carry a much higher risk 
of CVD than those who have T2DM alonen(4). 
Diabetes mellitus (DM) and related 
complications are associated with long-term damage 
and failure of various organ systems. It induces 
changes in the microvasculature, causing 
extracellular matrix protein synthesis and capillary 
basement membrane thickening which are the 
pathognomic features of diabetic microangiopathy, 
these changes in conjunction with advanced 
glycation end products oxidative stress, low grade 
inflammation and neovascularization of vasa 
vasorum can lead to vascular complications (5). 
Rapid urbanization and major changes in lifestyle 
could be driving this complications (6). 
Evidence supported that nearly 70-80% of the 
population with DM was diagnosed with MetS (7). 
Dyslipidemia and other characteristics of MetS are 
also common in Ethiopia. In a study of 950 DM 
patients in Ethiopia, the components of MetS were 
reported: hypertension  in 46.5%, obesity in 23.4% 
and dyslipidemia in 63.5% (8). In addition, a meta-
analysis also reported 19.6%  prevalence of 
hypertension in Ethiopian (9). 
Another study in Ethiopia reported that MetS 
prevalence among hypertensive patients was 40.7% 
and 39.3% (10). The more components of the MetS 
that are evident, the higher is the CVD mortality rate 
(11). Besides, genetics, physical inactivity, ageing, a 
pro-inflammatory state and hormonal changes may 
also have a causal effect, but the role of these vary 
depending with ethnic group (12). A study reported 
higher prevalence of the MetS (41.1%) in primary 
aldosteronism that confirms the negative effect of 
aldosterone excess on glucose metabolism (13). 
Currently, the prevalence of T2DM is rising in 
Ethiopia Therefore, the aim of the study was to 
determine the prevalence and components of the 
MetS among T2DM patients at University of Gondar 
Hospital, Northwest Ethiopia.  
 
METHODS AND MATERIALS 
       
Study design, period and area: A cross-sectional 
study was conducted from June to July 2015, at 
University of Gondar Hospital, Ethiopia. Gondar 
Town is located at 738 km far from Addis Ababa, 
the capital city of Ethiopia. University of Gondar 
Hospital plays an important role in teaching, 
research and community service. The hospital gives 
service for more than 8000 diabetic patients. 
Sample size and sampling technique: The sample 
size was estimated based on single population 
proportion formula taking 95% confidence interval 
(CI)  and 84.8%  prevalence of MetS among T2DM 
patients from Malaysia (14). Thus, during the study 
period, approximately 800 T2DM patients were 
estimated to visit the chronic disease clinic. Since the 
population during the study period was below 
10,000, the sample size correction formula was 
applied. Then, a total of 159 T2DM patients were 
included in the study. To select participants from the 
study population, direct patient flow was checked for 
one week in the chronic diseases clinic. The study 
participants were chosen at regular intervals from 
their sequence of follow-up visit using systematic 
random sampling techniques.  
Study participants: One hundred fifty-nine T2DM 
patients on follow-up care at the Universityof 
Gondar Hospital were recruited. All T2DM patients 
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attending the Hospital’s Chronic Illness Clinic, 
during the study period, were eligible to participate 
in the study. Participants who were pregnant, 
lactating mothers, patients with history of other 
chronic diseases and patients on treatment for lipid 
lowering were excluded from the study. 
 
Definition of metabolic syndrome 
IDF definition: According to  IDF criteria, patients 
were classified as having MetS if they had 
abdominal obesity (waist circumference of ≥94 cm 
for men and ≥80 cm women) plus two of any of the 
following components: raised TG level (≥150 
mg/dL), reduced HDL-c (<40 mg/dL in males and 
<50 mg/dL in females), raised BP (systolic BP ≥130 
or diastolic BP ≥85 mmHg) or treatment of 
previously diagnosed hypertension(3). 
Modified NCEP-ATP III definition: According to 
the NCEP-ATP III criteria, patients were classified 
as having MetS if they had three or more of the 
following four risk factors:  abdominal obesity (waist 
circumference >102 cm in males and >88 cm in 
females), TG (≥150 mg/dl), reducedHDL-c (<40 
mg/dl in males and <50 mg/dl in females), 
higharterial BP (≥130/85 mmHg) (15). 
Data collection and laboratory investigations 
Data on the characteristics of study participants: 
Data on socio-demographic characteristics were 
collected by trained nurses from University of 
Gondar Hospital Chronic Illness Clinic by using 
semi-structured questionnaire. The data collection 
was conducted in accordance with the WHO STEP 
wise approach  for non-communicable disease 
surveillance in developing countriesmanual (16). 
The systolic and diastolic BP were taken by qualified 
personnel using a standard mercury type analogue 
sphygmomanometer and stethoscope. To improve 
the reliability of the measurement duplicate 
measurements were taken from the upper arm with 
the hand at the heart level after the patient had been 
sitting for 5 minutes, and the averaged values were 
recorded as the final BP of the patient.  
Anthropometric measurements: Anthropometric 
data were collected according to WHO STEPS 
manual (16). Weight was measured in kilograms 
(kg) using the WHO weighing scale at a precision of 
0.1kg. Height was measured using standiometer 
while weight was recorded after measuring the 
patient bare-footed and with light clothes using a 
weight balance. On the other hand, the height 
measurement is recorded to the nearest 0.1cm. Waist 
circumference (WC) in centimeter was measured at 
the midpoint between the lowermost rib and the iliac 
crest. 
Laboratory investigations: Five milliliter fasting 
blood sample was collected in plane test tubes, and 
serum was extracted. The extracted serum was 
investigated for Glucose and lipid profile levels 
using Bio systems A25 (Costa Brava, Spain) 
automated clinical chemistry analyzer following the 
manufacturer’s instructions. Triglycerides, HDL-c, 
LDL-c, total cholesterol was determined by specific 
enzymatic method, and glucose was determined by 
glucose oxidase method. 
Data analysis and interpretation: Data were 
entered into EPI INFO computer software and 
exported to SPSS version 20 (IBM, USA). The data 
were tested for normality. Frequency distributions of 
the study participants were explored. Continuous 
variables were expressed as mean ± standard 
deviation and categorical variables were expressed 
as percentage. Bivariate and multivariable binary 
logistic regression analyses were used to evaluate 
associated risk factors for the outcome variable. P-
value ≤ 0.2 was used as cutoff value to include 
variables for multivariable logistic regression model. 
The prevalence estimates for MetS were determined 
according to the two definitions separately. A P-
value ≤ 0.05was considered statistically significant. 
Data management and quality control: The quality 
of the data was checked for coherence and 
completeness. The questionnaire was pre-tested for 
its accuracy and consistency prior to actual data 
collection. Trained nurses working in the chronic 
diseases follow-up clinic were involved in data 
collection. Furthermore, the principal investigator 
gave feedback and corrections on daily basis to the 
data collectors. The proper functioning of 
instruments, laboratory reagents and technical 
performance was checked by using quality control 
samples. Normal and pathological control samples 
were run daily in order to check the optimal 
reactivity of the reagent and functionality of the 
analyzer. Therefore, to maintain the quality of the 
result, pre-analytical, analytical and post-analytical 
pre-cautions of quality were considered. Finally, the 
sample was processed in the clinical chemistry 
laboratory based on the manufacturer’s manual.  
 
RESULTS 
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Socio-demographic and behavioral characteristics 
of the participants: The study population comprised 
159T2DM patients; of these, 95(59.7%) were 
females. The mean (±SD) age of the study 
participants was (49.8±8.7) years. The majority, 
146(91.6%), of the study participants were urban 
residents, and 18(21.3%) were smokers at the time of 
data collection (Table 1). 
 
Table 1: Socio-demographic and behavioral characteristics according to sex of T2DM patients at the 
University of Gondar Hospital, Northwest Ethiopia (n=159). 
 
Variables  Male (N %)  Female (N %)   Total N (%) P-value 
Age    0.039 
           25-35 5(25.0) 15(75.0) 20(12.6)  
           36-46 20(60.6) 13(39.4) 33(20.8)  
           47-57 22(34.9) 41(65.1) 63(39.6)  
            ≥58 17(39.5) 26(60.5) 43(27.0)  
Residence     0.891 
           Urban 59(40.4) 87(59.6) 146(91.8)  
           Rural  5(39.0) 8(61.0) 13(8.2)  
Religion     0.452 
        Orthodox 58(40.6) 85(59.4) 143(89.9)  
        Muslim 3(27.3) 8(72.7) 11(6.9)  
        Protestant 3(60.0) 2(40.0) 5(3.2)  
Educational status    0.000 
         Illiterate 7(16.3) 36(83.7) 43(27.0)  
         Primary school 19(47.5) 21(52.5) 40(25.2)  
        Secondary school 9(31.0) 20(69.0) 29(18.2)  
        College/University 29(61.7) 18(38.3) 47(29.6)  
Marital status    0.000 
         Single 2(25.0) 6(75.0) 8(5.0)  
         Married  61(58.3) 60(49.6) 121(76.1)  
        Widowed 1(4.8) 20(95.2) 21(13.2)  
        Divorced 0(0) 9(100) 9(5.7)  
Occupation      
     House wife 0(0) 61(100) 61(38.4) 0.000 
     Government worker 28(58.3) 20(41.7) 48(30.2)  
     Non-govtal organization 13(86.7) 2(13.3) 15(9.4)  
     Merchant 13(59.1) 9(40.9) 22(13.8)  
      Farmer 10(76.9) 3(23.1) 13(8.2)  
Monthly income     0.050 
<1000 14(29.8) 33(70.2) 47(29.6)  
1000-2000 8(27.6) 21(72.4) 29(18.2)  
2001-3000 14(51..9) 13(48.1) 27(17.0)  
>3001 28(50.0) 28(50.0) 56(35.2)  
Physical activity    0.045 
         Yes  31(50.0) 31(50.0) 62(39.0)  
         No  33(34.0) 64(66.0) 97(61.0)  
Alcohol in the last 1 month         0.000 
      Yes  31(66.0) 16(34.0) 47(29.6)  
      No  33(29.5) 79(69.5) 112(70.4)  
Current smoker     0.011 
      Yes  13(72.2) 5(27.8) 18(21.3)  
       No  51(36.2) 90(63.8) 141(88.7)  
Table t. Continued…. 
Sleeping duration/24hr    0.48 
       6-8 hour 33(38.4) 53(61.6) 86(54.1)  
              
              The Prevalence of Metabolic Syndrome…                                            Belete B. et al.                      
 
 
DOI:  http://dx.doi.org/10.4314/ejhs.v28i5.16 
 
649 
       Less than 6 hour 11(52.4) 10(47.6) 21(13.2)  
       Greater than 8 hour 20(38.5) 32(61.5) 52(32.7)  
Over all total 64(40.3%) 95(59.7%) 159(100%)  
Lipid profiles, anthropometric and clinical 
characteristics of T2DM patients: Among the total 
study participants, abnormal concentrations of total 
cholesterol (64.2%), LDL-c (57.9%), low HDL-c 
(31.5%) and high TG (62.3%) were observed in 
females compared to their male counterparts (Table 
2). 
 
Table 2: Lipid profiles, anthropometric and clinical characteristics according to sex of T2DM patients at 
University of Gondar Hospital, northwest Ethiopia (n=159). 
 
 
Variables  Male N (%) Female N (%) Total N (%) P-value 
Total cholesterol (mg/dl)    0.313 
   <200 33(42.9) 44(57.1) 77(35.8)  
   ≥200  31(37.8) 51(62.2) 82(64.2)  
LDL cholesterol (mg/dl)    0.203 
     <130 30(44.8) 37(55.2) 67(42.1)  
     ≥130  34(37.0) 58(63.0) 92(57.9)  
HDL Cholesterol (mg/dl)     <0.05 
<40 (men), <50 (women) 22(44.0) 28(56.0) 50(31.5)  
  ≥40 (men), ≥50 (women) 42(38.5) 67(61.5) 109(68.5)  
Triglyceride (mg/dl)    0.60 
   <150  19(31.7) 41(68.3) 60(37.7)  
   ≥150 45(45.5) 54(54.5) 99(62.3)  
BMI        0.901 
     Under weight 1(33.3) 2(66.7) 3(1.9)  
    Normal weight 29(42.7) 39(57.3) 68(42.8)  
    Over weight 28(40.0) 42(60.0) 70(44.0)  
    Obesity  6(33.3) 12(66.7) 18(11.3)  
SBP(mmHg)    0.460 
   <130 31(41.3) 44(58.7) 75(47.2)  
   ≥130 33(39.3) 51(60.7) 84(52.8)  
DBP(mmHg)    0.558 
   <85 51(40.2) 76(59.8) 127(79.9)  
   ≥85 13(40.6) 19(59.4) 32(20.1)  
Waist circumference (cm)    >0.05 
   <94(men), ≤80(women) 40(30.3) 26(69.7) 66(41.5)  
  ≥94(men), >80(women) 24(25.2) 69(74.2) 93(58.5)  
Duration of DM (in year)    0.027 
<5  37(49.3) 38(50.7) 75(47.2)  
 ≥5  27(32.1) 57(67.9) 84(52.8)  
Glycemic control / FBS(mg/dl)    0.546 
 Good (≤130) 28(43.1) 37(56.9) 65(40.9)  
  Poor(>130) 36(38.3) 58(61.7) 94(59.1)  
Note: DBP: Diastolic Blood Pressure, SBP: Systolic Blood Pressure, BMI: Body Mass Index, LDL: Low density Lipoprotein, 
HDL: High Density Lipoprotein, mmHg: Millimeter Mercury 
 
The prevalence of MetS and individual 
components of MetS based on NCEP-ATP III and 
IDF criteria: The overall prevalences of MetS based 
on NCEP-ATPIII and IDF criteria were 66.7% 
(95%CI: 59.7-74.2) and 53.5% (95% CI: 45.3-61.0), 
respectively.  The frequencies of MetS components 
were the highest for elevated TG (56.6%) and 
elevated blood pressure (55.4%) using NCEP-
ATPIII, and central obesity (61.0%) and elevated TG 
(62.3%) in IDF criteria. The prevalence and all its 
individual components of MetS were higher among 
female in both criteria (Table 3). 
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Table 3: The prevalence of MetS and its components according to NCEP-ATPIII and IDF criteria among T2DM 
patients at University of Gondar Hospital, northwest Ethiopia (n=159). 
 
 
 
Variables  
Diagnostic definitions of Metabolic Syndrome 
NCEP-ATPIII criteria             IDF criteria  
Male 
N (%) 
Female 
 N (%) 
Total 
 N (%)  
P-value 
 
Male  
N (%) 
Female 
 N (%) 
Total 
 N (%) 
P-Value 
Central obesity  10(14.5) 59(85.5) 69(43.4) 0.000 24(24.7) 73(75.3) 97(61.0) 0.000 
Increased 
Triglyceride 
45(45.5) 54(54.5) 99(56.6) 0.000 45(45.5) 54(54.5) 99(62.3) 0.000 
Low HDL 
cholesterol 
22(42.3) 30(57.7) 52(32.7) 0.001 22(42.3) 30(57.7) 52(32.7) 0.001 
Elevated blood 
pressure 
35(39.8) 53(60.2) 88(55.4) 0.000 35(39.8) 53(60.2) 88(55.3) 0.000 
Overall Prevalence 
of MetS 
36(34.0) 70(66.0) 106(66.7) 0.020 23(35.9) 62(65.3) 85(53.5) 0.000 
Note: NCEP-ATPIII: National Cholesterol Education program Adult Treatment Panel III  
           IDF: International Diabetes Federation 
 
Clustering of components of MetSbased on 
NCEP-ATPIII and IDF criteria among T2DM 
patients: According to the NCEP-ATP III criteria, 
57.5% males and 42.5% females had one additional 
MetS component. On the other hand, 36.7% males 
and 63.3% females had 2 additional components of 
MetS (Table 4). 
Factors associated with prevalence of MetS among 
T2DM patients attending at University of Gondar 
Hospital: The NCEP-ATP III criteria on the 
multivariable logistic regression analysis indicated 
that age 47-57 years (AOR= 9.22; 2.36, 36.02), age 
≥58 years (AOR=9.90; 95%CI: 2.19, 44.72) and 
having FBS > 130mg/dl (AOR=2.88; 955CI: 1.16, 
7.16) were found to have significant associations 
with MetS. Similarly, applying the IDF criteria for 
MetS, the multivariable regression analysis showed 
that being female (AOR =3.98; 95%CI: 1.66, 9.54), 
age between 47-57 years (AOR= 7.9; 1.63, 38.41), 
age ≥58 years (AOR=20.9; 95%CI: 3.79, 114.8), 
having abnormal BMI (AOR=5.12; 95%CI: 2.02, 
12.93), duration  of ≥5 years since diagnosis of 
T2DM(AOR=  3.14; 95%CI: 1.24, 7.97) and being 
FBS >130mg/dl (AOR=2.53; 95%CI: 1.01, 6.32) 
were found to have significant associations with 
MetS (Table 5). 
 
Table 4: Clustering of components of MetSaccording to NCEP-ATPIII and IDF criteria among T2DM patients at 
University of Gondar Hospital, northwest Ethiopia (n=159). 
 
 
No of component(s) 
 Diagnostic Definitions of Metabolic Syndrome 
NCEP-ATPIII criteria  IDF criteria  
Male 
N (%) 
Female N 
(%) 
Total 
 N (%)  
Male  
N (%) 
Female 
 N (%) 
Total 
 N (%) 
0  5(38.5) 8(61.5) 13(8.2) 4(57.1) 3(42.9) 7(4.4) 
At least 1 23(57.5) 17(42.5) 40(25.2) 19(52.8) 17(47.2) 36(22.6) 
At least 2 22(36.7) 38(63.3) 60(37.7) 21(34.4) 40(65.6) 61(38.4) 
At least 3 11(30.6) 25(69.4) 36(22.6) 15(35.7) 27(64.3) 42(26.4) 
At least 4 3(30.0) 7(70.0) 10(6.3) 5(38.5) 8(61.5) 13(8.2) 
Note: NCEP-ATPIII:National Cholesterol Education program Adult Treatment Panel, IDF: International Diabetes Federation 
 
DISCUSSION 
MetS is a cluster of the most dangerous heart attack 
risk factors: diabetes and raised fasting plasma 
glucose, abdominal obesity, elevated TG, low HDL 
and high blood pressure (1, 4). The overall 
prevalence of MetS in the study was 53.5% in IDF 
whereas 66.7% in the NCEP-ATPIII criteria. 
Previous studies also pointed out similar prevalence 
among T2DM population, Nigeria 62.5% (17) and 
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Table 5: Bivariable and multivariable logistic regression analysis of factors associated with MetS among T2DM patients at University of Gondar Hospital, northwest 
Ethiopia (n=159). 
 
 
Variables 
NCEP-ATPIII criteria                IDF criteria 
MetS  
N (%) 
No MetS N (%) COR(95%CI) AOR(95%CI) MetS 
N (%) 
No MetS 
N (%) 
COR (95%CI) AOR (95%CI 
Sex   Male 36(56.3) 28(43.8) 1.00 1.00 23(35.9) 41(64.1) 1.00 1.00 
       Female  70(73.7) 25(26.3) 2.18(1.11-4.27)* 2.0(0.79-5.08) 62(65.3) 33(34.7) 3.35(1.73, 6.50)* 3.98(1.66-9.54)* 
Age   25-35 7(35) 13(65) 1.00 1.00 4(20.0) 16(80.0) 1.00 1.00 
         36-46 9(27.3) 24(72.7) 0.69(0.21-2.30) 1.39(0.33-5.86) 7(21.2) 26(78.8) 1.08(0.27-4.27) 2.58(0.43-15.43) 
          47-57 53(84.1) 10(15.9) 9.84(3.15-30.79)* 9.22(2.36-36.02)* 40(63.5) 23(36.5) 6.96(2.08-23.32)* 7.9(1.63-38.41)* 
            ≥58 37(86.1) 6(13.9) 11.45(3.25-40.39)* 9.90(2.19-44.72)* 34(79.1) 9(20.9) 15.1(4.04-56.52)* 20.9(3.79-114.8)* 
BMI(Kg/m2)         
≤ 25 47(62.5) 25(37.5) 1.00 1.00 27(37.5) 45(62.5) 1.00 1.00 
>25 59(67.8) 28(32.2) 1.12(0.58-2.17) 0.76(0.30-1.95) 58(66.7) 29(33.3) 3.33(1.74-6.40)* 5.12(2.02-12.93)* 
Duration of DM          
      <5 years 36(48.0) 39(52.0) 1.00 1.00 25(33.3) 50(66.7) 1.00 1.00 
      ≥5 years 70(83.3) 14(16.7) 5.42(2.61-11.25)* 2.63(1.00-6.93) 60(71.4) 24(28.6) 5.0(2.548-9.813)* 3.14(1.24-7.97)* 
FBS(mg/dl)         
≤130 29(44.6) 36(55.4) 1.00 1.00 23(35.4) 42(64.6) 1.00 1.00 
>130 77(81.9) 17(18.1) 5.62(2.74-11.52)* 2.88(1.16-7.16)* 62(66.0) 32(34.0) 3.54(1.82-6.87)* 2.53(1.01-6.32)* 
Physical activity         
         Yes  33(45.8) 39(54.2) 1.00 1.00 27(37.5) 45(62.5) 1.00 1.00 
          No  73(83.9) 14(16.1) 6.16(2.95-12.87)* 0.42(0.17-1.07) 58(66.7) 29(33.3) 3.33(1.74-6.40)* 0.63(0.26-1.55) 
Alcohol in the last 1 month             
      Yes  70(73.7) 25(26.3) 2.18(1.11-4.27)* 2.04(0.81-5.15) 52(54.7) 43(45.3) 1.14(0.60-2.14) 1.05(0.42-2.58) 
      No  36(55.4) 28(44.6) 1.00 1.00 33(50.8) 31(49.2) 1.00 1.00 
Sleeping duration/24hr         
     6-8 hour 49(57.0) 37(43.0) 1.00 1.00 41(47.8) 45(52.3) 1.00 1.00 
   <6 hour 17(81.0) 4(19.0) 3.21(0.99-10.33) 1.49(0.33-6.81) 10(47.6) 11(52.4) 0.99(0.38-2.59) 0.83(0.23-3.03) 
  >8 hour 40(76.9) 12(23.1) 2.52(1.16-5.46)* 1.01(0.36-2.85) 34(63.4) 18(34.6) 2.07(1.02-4.22)* 1.67(0.61-4.58) 
Note: *Statistically significant association, 1: Reference category, NCEP-ATPIII: National Cholesterol Education Program Adult Treatment Panel III, IDF: International Diabetes Federation, BMI: 
Body Mass Index, FBS: Fasting Blood Sugar, AOR: Adjusted Odds Ratio, COR: Crude Odds Ratio, CI: Confidence Interval 
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Ghana 58%(18). Conversely, higher rate of MetS than 
the finding of this study was reported among DM 
patients 70-80 % (7), 76% in Abbottabad (19) 
according to NCEP-ATPIII and 66% based on IDF 
criteria (20). Other previous studies also reported 
higher prevalence of  MetS in Nepalese (73.9%) and 
(66.8%) (21), Malaysia (96.1%),  (84.8%) (14) T2DM 
patients according to NCEP ATP III and IDF 
definitions, respectively.  
Lower prevalence of MetS was reported in T2DM 
patients in Bosnia and Herzegovina (47.91%) (22), in  
Ethiopian hypertensive patients (40.7%) and (39.3%) 
(10) using NCEP-ATPII and IDF criteria respectively. 
These differences in the prevalence of MetS can be 
explained by the interaction of genetic and 
environmental factors, rapid urbanization and the 
adoption of unhealthy lifestyle which predispose 
individuals to different risk factors of MetS (6). 
The prevalence of the MetS is strongly dependent 
on the different cut-off points and sets of criteria used 
by different definitions. In this study, slightly higher 
prevalence of MetS was observed by ATP III definition 
in comparison with IDF (66.7% vs.53.5 %). It could be 
attributed to the relative flexibility of the ATP III in 
which abdominal obesity is not considered as a 
prerequisite for the diagnosis and to the fact that criteria 
are more broadly focused on specific cardiovascular 
risk factors. Although it has been well understood that 
the international anthropometric cutoffs for detection of 
body fatness and risk of MetS are not appropriate for 
Ethiopians and some Asian countries to determine 
MetS.Ethiopians have higher body fat at a relatively 
low BMI because of the slender body frame compared 
with a Caucasians or black person from another country 
which predisposes them to very higher risk of MetS, 
T2DM and CVD than any other population in the world 
(23). Except for this difference, the ATP III and IDF 
definitions are essentially fair as seen by the degree of 
agreement (kappa statistic= 0.472) which is in 
agreement with the Bangladesh study (24).  
In this study, central obesity and 
hypertriglyceridemia were most prevalent components 
of the MetS in agreement to a study in Ethiopia (8). 
This finding is not surprising given the observation that 
central obesity plays a key role in the development of 
the MetS and appears to precede the appearance of the 
other MetS components. However, it is pertinent to 
note that although the specific role of central obesity in 
patients with the MetS remains unexplained; active 
brown adipocytes which accumulate in central locations 
have been found to be metabolically active. A small 
proportion T2DM have all the components of the MetS 
in this study. This is in contradistinction to the report 
(25) who reported the absence of a combination of four 
components of MetS in their study participants. 
The frequency of individual MetS components 
were predominantly higher in females compared to 
males in both criteria with central obesity and 
hypertriglyceridemia predominantly elevated. It is 
consistent with the report of an earlier study (26) but 
conflicting with studies in Nepal which identfied 
central obesity as the most prevalent  and hypertension  
as the least prevalent components of MetS (21,27). 
From multivariable analysis, participants who had 
high BMI, longer duration of illness since T2DM 
diagnosis, age, sex and having poor glycemic control 
are significantly associated with MetS. There were 
variations in the prevalence of each of the distinct risk 
factors of MetS by sex. For instance, previous studies 
supported a significantly elevated body weight, WC, 
and low HDL-cholesterol, hypertensive, dyslipidemia 
and poor glycemic control observed in women than 
men (10,26). The observation of sex difference in body 
fat distribution, IR, sex hormones and the effect of 
glucose, pro-inflammatory state, decreased growth 
hormone secretion, hypogonadism and stress induced 
hyper-cortisolism could have casual effects although 
the role of these may vary depending on ethnic group 
(12). Spectacular advances in evidence based medicine 
have shown that diabetic middle aged women are 8 
times more likely to develop cardiovascular events than 
non-diabetic (28). According to a large population 
survey conducted, female diabetics were more obese 
compared to male diabetics (13% and 10%, 
respectively) (29). 
In our study, patients with MetS were sharply 
increased in the age groups of ≥58 years in both men 
and women, which was quite expected and supported 
by another study (8). On the contrary,  a study reported 
that there is  a sharp decline of the prevalence at very 
high age group due to increased frequency of death of 
individuals who were most susceptible to obesity-
related mortality such as CAD and cerebrovascular 
events (30).  
In this study, durations of illness and glycemic 
control were significantly associated with MetS which 
is supported by previous studies which reported that 
participants who had diabetes for over 5 years were 
found to have an 11.3 times risk of developing MetS 
(31). This is contrary to other findings (32) in which the 
prevalence of MetS decreased along with an increase in 
the duration of diabetes. Another study also found an 
association of the MetS with less duration of diabetes 
(33). This might be due to decreased BMI as a result of 
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medical intervention and better metabolic control, 
increasing awareness with the longer duration illness in 
DM patients. The association of the MetS with poor 
glycemiccontrol could be the result of lack of 
awareness and inadequate access to quality medical 
care. This is supported by a study  in Ghana which 
reported that dyslipidemia and MetS were associated 
with poor glycemic control (34). 
In this study, patients with longer duration of 
sleeping had a risk of developing MetS. However, it 
was not a significant predictor of the MetS in our 
multivariable logistic regression model. 
Epidemiological studies, consistently to  our study, 
showed that long sleep duration was associated with 
MetS (35). A meta-analysis of observational studies 
indicated that short and long sleep durations are risky 
behaviors for increasing the risk of MetS (36). On the 
contrary, a number of studies in adults demonstrated an 
association between short sleep duration and MetS (37-
39). The limitation of this study was its  cross-sectional 
nature amongst patients which limits our causal 
inference.  
The prevalence of MetS and its components using 
NCEP-ATPIII and IDF criteria amongst persons with 
T2DM was high. Longer duration of DM, poor 
glycemic control, high BMI, increased age and female 
sex were significantly associated with MetS. Education 
on appropriate glycemic control and healthy life style 
modification should be provided to control and reduce 
diabetes-related morbidity and mortality. 
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